A placebo-controlled study of raloxifene added to risperidone in men with chronic schizophrenia

Acta Medica Iranica

Volumn 53, Issue 6, 2015, Pages 337-345

  Khodaie Ardakani, Mohammad Reza ^a   Khosravi, Mohsen ^b   Zarinfard, Razieh ^b   Nejati, Somayeh ^a   Mohsenian, Ali ^a   Tabrizi, Mina ^c   Akhondzadeh, Shahin ^b  

^a UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Estrogen; Men; Raloxifene; Schizophrenia

Indexed keywords

PLACEBO; RALOXIFENE; RISPERIDONE; NEUROLEPTIC AGENT;

ADJUVANT THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HAMILTON DEPRESSION RATING SCALE; HEADACHE; HUMAN; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; RASH; SCHIZOPHRENIA; TREATMENT OUTCOME; WEIGHT GAIN; XEROSTOMIA; CONTROLLED STUDY; DRUG COMBINATION; PSYCHOLOGICAL RATING SCALE; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; DEPRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; RALOXIFENE HYDROCHLORIDE; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84930035107     PISSN: 00446025     EISSN: 17359694     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Davidson M, Caspi A, Noy S. The treatment of schizophrenia: from premorbid manifestations to the first episode of psychosis. Dialogues Clin Neurosci 2005;7(1):7-16
2. Rössler W, Salize HJ, van Os J, et al. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 2005;15(4):399-409
3. Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci 2000;250(6):274-85
4. Charrier N, Chevreul K, Durand-Zaleski I. The cost of schizophrenia: a literature review. Encephale 2013;39(Suppl 1):S49-56
5. Carr VJ, Neil AL, Halpin SA, et al. Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study. Aust N Z J Psychiatry 2003;37(1):31-40
6. Jackson D, Kirkbride J, Croudace T, et al. Meta-analytic approaches to determine gender differences in the ageincidence characteristics of schizophrenia and related psychoses. Int J Methods Psychiatr Res 2013;22(1):36-45
7. McGrath J, Saha S, Welham J, et al. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2004;2(1):13
8. Leung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand 2000;401(Suppl):3-38
9. Usall J, Busquets E, Araya S, et al. Gender differences in schizophrenia. A literature review. Actas españolas Psiquiatr 2000;28(3):178-85
10. Sánchez R, Téllez G JL. Age of onset symptoms and gender in schizophrenia spectrum disorders. Biomedica 2012; 2(2):206-13
11. Häfner H. Gender differences in schizophrenia. Psychoneuroendocrinology 2003;28(Suppl 2):17-54
12. Kulkarni J, Gavrilidis E, Worsley R, et al. Role of estrogen treatment in the management of schizophrenia. CNS Drugs 2012;26(7):549-57
13. Smith S. Gender differences in antipsychotic prescribing. Int Rev Psychiatry 2010;22(5):472-84
14. Usall J, Suarez D, Haro JM. Gender differences in response to antipsychotic treatment in outpatients with schizophrenia. Psychiatry Res 2007;153(3):225-31
15. Goldstein JM, Link BG. Gender and the expression of schizophrenia. J Psychiatr Res 1988;22(2):141-55
16. Zeinoddini A, Ahadi M, Farokhnia M, et al. L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial. J Psychiatr Res 2014;59:125-31
17. Hosseini SM, Farokhnia M, Rezaei F, et al. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial. Eur Neuropsychopharmacol 2014;24(6):846-55
18. Kulkarni J, Riedel A, de Castella AR, et al. Estrogen - a potential treatment for schizophrenia. Schizophr Res 2001;48(1):137-44
19. Hayes E, Gavrilidis E, Kulkarni J. The role of oestrogen and other hormones in the pathophysiology and treatment of schizophrenia. Schizophr Res Treatment 2012;2012:540273
20. Kulkarni J. Oestrogen--a new treatment approach for schizophrenia? Med J Aust 2009;190(4 Suppl):S37-8
21. Akhondzadeh S, Mokhberi K, Amini H, et al. Is there a relationship between estrogen serum level and symptom severity throughout the menstrual cycle of patients with schizophrenia? Therapy 2005;2:745-51
22. Chavez C1, Hollaus M, Scarr E, et al. The effect of estrogen on dopamine and serotonin receptor and transporter levels in the brain: an autoradiography study. Brain Res 2010;1321:51-9
23. Landry M, Paolo D. Effect of chronic estradiol, tamoxifen or raloxifene treatment on serotonin 5-HT 1A receptor. Brain Res Mol Brain Res 2003;112(1-2):82-9
24. Huber TJ, Rollnik J, Wilhelms J, et al. Estradiol levels in psychotic disorders. Psychoneuroendocrinology 2001;26(1):27-35
25. Kulkarni J, de Castella A, Smith D, et al. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr Res 1996;20(3):247-52
26. Riecher-Rössler A, Häfner H, Dütsch-Strobel A, et al. Further evidence for a specific role of estradiol in schizophrenia? Biol Psychiatry 1994;36(7):492-4
27. Kulkarni J. Women and schizophrenia: a review. Aust N Z J Psychiatry 1997;31(1):46-56
28. Riecher-Rössler A, Häfner H. Schizophrenia and oestrogens--is there an association? Eur Arch Psychiatry Clin Neurosci 1993;242(6):323-8
29. Seeman M V, Lang M. The role of estrogens in schizophrenia gender differences. Schizophr Bull 1990;16(2):185-94
30. Akhondzadeh S, Nejatisafa AA, Amini H, et al. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(6):1007-12
31. Kulkarni J, de Castella A, Fitzgerald PB, et al. Estrogen in severe mental illness: a potential new treatment approach. Arch Gen Psychiatry 2008;65(8):955-60
32. Ghafari E, Fararouie M, Shirazi H. Combination of estrogen and antipsychotics in the treatment of women with chronic schizophrenia. Clin Schizophr Relat Psychoses 2013;6(4):172-6
33. Grigoriadis S, Seeman M. The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women. Can J Psychiatry 2002;47(5):437-42
34. Kulkarni J, Gavrilidis E, Wang W, et al. Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Mol Psychiatry 2014. [Epub ahead of print]
35. Sayed Y, Taxel P. The use of estrogen therapy in men. Curr Opin Pharmacol 2003;3(6):650-4
36. Kulkarni J, de Castella A, Headey B, Marston Net al. Estrogens and men with schizophrenia: is there a case for adjunctive therapy? Schizophr Res 2011;125(2-3):278-83
37. Chua WL, de Izquierdo SA, Kulkarni J, et al. Estrogen for schizophrenia. Cochrane database Syst Rev 2005;(4):CD004719
38. Prentice RL. Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke. Semin Reprod Med 2014;32(6):419-25
39. Kulkarni J, Gurvich C, Lee SJ, et al. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 2010;35(8):1142-7
40. Raveendranathan D, Shivakumar V, Jayaram N, et al. Beneficial effects of add-on raloxifene in schizophrenia. Arch Womens Ment Health 2012;15(2):147-8
41. Kianimehr G, Fatehi F, Hashempoor S, et al. Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial. Daru 2014;22(1):55
42. Huerta-Ramos E, Iniesta R, Ochoa S, et al. Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebocontrolled trial. Eur Neuropsychopharmacol 2014;24(2):223-31
43. Usall J, Huerta-Ramos E, Iniesta R, et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebocontrolled trial. J Clin Psychiatry 2011;72(11):1552-7
44. Kulkarni J, Gavrilidis E, Worsley R, et al. The Role of Estrogen in the Treatment of Men with Schizophrenia. Int J Endocrinol Metab 2013;11(3):129-36
45. Kirkpatrick B, Fenton WS, Carpenter WT Jr, et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006;32(2):214-9
46. Murphy BP, Chung Y-C, Park TW, et al. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 2006;88(1-3):5-25
47. Littleton-Kearney MT, Ostrowski NL, Cox DA, et al. Selective estrogen receptor modulators: tissue actions and potential for CNS protection. CNS Drug Rev 2002;8(3):309-30
48. Huang Y, Huang YL, Lai B, et al. Raloxifene acutely reduces glutamate-induced intracellular calcium increase in cultured rat cortical neurons via inhibition of highvoltage- activated calcium current. Neuroscience 2007;147(2):334-41
49. Iritani S. Neuropathology of schizophrenia: a mini review. Neuropathology 2007;27(6):604-8
50. Usall J, Huerta-Ramos E, Iniesta R. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebocontrolled trial. J Clin Psychiatry 2011;72(11):1552-7
51. Kulkarni J, Gurvich C, Gilbert H, et al. Hormone modulation: a novel therapeutic approach for women with severe mental illness. Aust N Z J Psychiatry 2008;42(1):83-8
52. Yaffe K, Krueger K, Cummings SR, Blackwell T, et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry 2005;162(4):683-90
53. Hayes FJ, Seminara SB, Decruz S, et al. Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback. J Clin Endocrinol Metab 2000;85(9):3027-35
54. Henderson VW, Lobo RA. Hormone therapy and the risk of stroke: perspectives 10 years after the Women’s Health Initiative trials. Climacteric 2012;15(3):229-34.